Literature DB >> 1458487

Growth suppression mediated by transfection of p53 in Hut292DM human lung cancer cells expressing endogenous wild-type p53 protein.

J F Cajot1, M J Anderson, T A Lehman, H Shapiro, A A Briggs, E J Stanbridge.   

Abstract

This study was undertaken to analyze the effect of wild-type p53 transfection on the growth potential of a human lung cancer cell line Hut292DM expressing endogenous wild-type p53. Transfection efficiencies obtained with either the wild-type or a mutant p53 complementary DNA revealed a significant decrease in the number of colonies obtained with the wild-type p53 as compared to the mutant p53 complementary DNA (27%) or control vector DNA only (20%), suggesting that wild-type p53 inhibited the growth of Hut292DM cells. A series of wild-type and mutant p53 transfection clones were then analyzed for the presence and expression of the exogenous p53 gene. Polymerase chain reaction amplification revealed that 98% of mutant p53 transfection clones analyzed contained the exogenous p53 gene as opposed to 47% for wild-type p53 clones. The majority of mutant p53 clones expressed high levels of exogenous p53 mRNA and protein as analyzed by Northern and Western blots, respectively. In contrast, all wild-type p53 clones analyzed failed to express exogenous p53 mRNA transcript or protein of a normal size. Aberrant-size p53 mRNA was detected in two wild-type p53 clones (X833.W2 and W18), and Western blot analysis revealed that these clones expressed truncated p53 proteins (M(r) 45,000 and 33,000 respectively). No difference in proliferation rates in vitro or in tumorigenic potential in nude mice were observed between mutant p53 clones or control cell lines. In contrast, a wild-type p53 clone (X833.W2) exhibited a significantly reduced tumorigenic potential in nude mice, whereas its in vitro proliferation rate was comparable to parental Hut292DM cells. The data indicate that exogenous expression of wild-type p53 is incompatible with Hut292DM lung cancer cell proliferation in vitro and suggest that p53-mediated growth control in vitro and in vivo may be dissociated and exerted by separate domains of the p53 protein.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1458487

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Inhibitory effect of IGF- II antisense RNA on malignant phenotype of hepatocellular carcinoma.

Authors:  Dong-Hua Yang; Ming-Qing Zhang; Jiang Du; Chong Xu; Qiao-Ming Liang; Ji-Fang Mao; Han-Rong Qin; Zi-Rong Fan
Journal:  World J Gastroenterol       Date:  2000-04       Impact factor: 5.742

2.  Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of experimental intracranial human malignant glioma.

Authors:  C Cirielli; K Inyaku; M C Capogrossi; X Yuan; J A Williams
Journal:  J Neurooncol       Date:  1999-06       Impact factor: 4.130

Review 3.  The p53 tumor suppressor gene in breast cancer.

Authors:  R M Elledge; D C Allred
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

4.  Progression toward tumor cell phenotype is enhanced by overexpression of a mutant p53 tumor-suppressor gene isolated from nasopharyngeal carcinoma.

Authors:  Y Sun; K Nakamura; E Wendel; N Colburn
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

5.  Single cell monitoring of growth arrest and morphological changes induced by transfer of wild-type p53 alleles to glioblastoma cells.

Authors:  E G Van Meir; K Roemer; A C Diserens; T Kikuchi; S A Rempel; M Haas; H J Huang; T Friedmann; N de Tribolet; W K Cavenee
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-14       Impact factor: 11.205

6.  Suppression of tumorigenic and metastatic potentials of human melanoma cell lines by mutated (143 Val-Ala) p53.

Authors:  S Rauth; A Green; J Kichina; A Shilkaitis
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

7.  CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas.

Authors:  Tomoyuki Fujita; Jun Igarashi; Erin R Okawa; Takahiro Gotoh; Jayanthi Manne; Venkatadri Kolla; Jessica Kim; Huaqing Zhao; Bruce R Pawel; Wendy B London; John M Maris; Peter S White; Garrett M Brodeur
Journal:  J Natl Cancer Inst       Date:  2008-06-24       Impact factor: 13.506

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.